Marksans Pharma Limited AI Stock Analysis
Want to see IN:MARKSANS full AI Analyst Report?
Marksans Pharma Limited (MARKSANS) AI Stock Analysis
Marksans Pharma Limited
(NSE:MARKSANS)
Marksans Pharma scores in the moderately favourable range, driven primarily by a strong financial profile: consistent double-digit revenue growth, stable mid-teens net margins, and a conservatively leveraged balance sheet with low debt and steadily compounding equity. The main fundamental caution is inconsistent conversion of profits into free cash flow during FY2024-FY2025, alongside a projected sharp drop in gross margin that needs to be monitored. Technically, the stock retains a healthy long-term uptrend well above its 200-DMA, though it is currently consolidating below its 50-DMA with neutral momentum readings. Valuation at 25x earnings is fair rather than cheap, and the negligible 0.29% dividend yield means returns depend on growth execution. Earnings call and corporate event data were unavailable and therefore excluded, with their weight redistributed across the remaining components.
Marksans Pharma Limited (MARKSANS) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 132.96B
- Dividend Yield
- 0.30%
- Average Volume (3M)
- 123.11K
- Price to Earnings (P/E)
- 24.2
- Beta (1Y)
- 1.00
- Revenue Growth
- 24.20%
- EPS Growth
- 59.18%
- Country
- India
- Employees
- 1,685
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - General
Marksans Pharma Limited Business Overview & Revenue Model
Company Description
Marksans Pharma Limited, along with its subsidiaries, operates internationally, engaging in the full spectrum of generic pharmaceutical formulation activities, from research and development and manufacturing to marketing, distribution, and sales. The...
Marksans Pharma Limited Financial Statement Overview
Summary
Solid fundamentals overall. Revenue has compounded at roughly 16-17% since FY2021 (₹13.7B to an estimated ₹29.5B in FY2026) with net margins held in the 12-17% band and net income rising steadily to a projected ₹4.18B (Income Statement: 68). The balance sheet is the standout strength, with debt-to-equity consistently below 0.15, equity growing from ₹8.9B to a projected ₹30.2B, and stable ~15% ROE (Balance Sheet: 72). Cash flow is the weak link (Cash Flow: 58) — operating cash conversion has been erratic (OCF/net income as low as 0.28 in FY2022 and 0.43 in FY2025) and free cash flow collapsed to ₹216M in FY2024 and ₹337M in FY2025 before a projected rebound to ₹3.5B in FY2026. Slowing top-line growth (~8% projected) and the sharp projected gross margin compression from ~56% to ~39% temper the score.
Income Statement
68PositiveBalance Sheet
72PositiveCash Flow
58Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.92B | 29.51B | 26.23B | 21.77B | 18.52B | 14.80B |
| Gross Profit | 13.90B | 11.57B | 14.79B | 11.03B | 9.31B | 7.32B |
| EBITDA | 8.04B | 6.03B | 5.29B | 5.09B | 3.99B | 3.01B |
| Net Income | 5.60B | 4.18B | 3.81B | 3.14B | 2.66B | 1.85B |
Balance Sheet | ||||||
| Total Assets | 43.60B | 38.61B | 32.40B | 26.81B | 21.90B | 16.40B |
| Cash, Cash Equivalents and Short-Term Investments | 11.24B | 9.90B | 7.05B | 7.00B | 7.19B | 3.47B |
| Total Debt | 4.65B | 3.43B | 3.22B | 2.44B | 1.23B | 1.11B |
| Total Liabilities | 9.92B | 8.08B | 7.50B | 5.95B | 4.25B | 4.17B |
| Stockholders Equity | 33.32B | 30.23B | 24.67B | 20.65B | 17.45B | 12.02B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 3.51B | 337.45M | 215.69M | 1.84B | 529.27M |
| Operating Cash Flow | 0 | 4.82B | 2.07B | 2.30B | 2.37B | 992.57M |
| Investing Cash Flow | 0 | -2.75B | -490.09M | -1.41B | -2.59B | -416.86M |
| Financing Cash Flow | 0 | -681.43M | -651.46M | -687.27M | 1.98B | 795.11M |
Marksans Pharma Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MARKSANS, the sentiment is Negative. The current price of 299.15 is below the 20-day moving average (MA) of 305.65, below the 50-day MA of 316.41, and above the 200-day MA of 248.36, indicating a neutral trend. The MACD of -2.45 indicates Positive momentum. The RSI at 44.49 is Neutral, neither overbought nor oversold. The STOCH value of 20.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:MARKSANS.
Marksans Pharma Limited Peers Comparison
Overall Rating
IN:CIPLA73Outperform
IN:GLAXO73Outperform
IN:PFIZER69Neutral
IN:GLAND66Neutral
IN:MARKSANS65Neutral
IN:SANOFI65Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | INR 1.14T | 39.55 | ― | 2.05% | -0.74% | -46.77% | |
| 73Outperform | INR 459.88B | 40.09 | ― | 2.10% | 12.12% | 20.03% | |
| 69Neutral | INR 176.12B | 20.50 | ― | 1.95% | 11.75% | 2.39% | |
| 66Neutral | INR 543.06B | 43.92 | ― | 0.61% | 21.90% | 56.28% | |
| 65Neutral | INR 135.56B | 24.19 | ― | 0.30% | 24.20% | 59.18% | |
| 65Neutral | INR 73.70B | 20.23 | ― | 3.85% | -5.74% | 2.30% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:MARKSANS | Marksans Pharma Limited | 299.15 | 110.62 | 58.68% | |
| IN:CIPLA | Cipla Ltd | 1416.00 | -73.91 | -4.96% | |
| IN:GLAND | Gland Pharma Ltd. | 3291.05 | 1513.45 | 85.14% | |
| IN:GLAXO | GlaxoSmithKline Pharmaceuticals Limited | 2714.65 | 301.11 | 12.48% | |
| IN:PFIZER | PFIZER LIMITED | 3849.70 | -1045.73 | -21.36% | |
| IN:SANOFI | Sanofi India Limited | 3200.15 | -1050.77 | -24.72% |
Marksans Pharma Limited Corporate Events
Marksans Pharma Files Q2 FY27 Earnings Call Transcript
Marksans Pharma Limited informed the exchanges on November 13, 2026, that it had submitted the transcript of its investor and analyst meeting on Q2 FY27 unaudited financial results, held on November 5, 2026. The transcript was also made available on...
Marksans Pharma Opens SEBI-Mandated Window for Re-Lodging Physical Share Transfers
Marksans Pharma Limited has announced the opening of a special window for shareholders to re-lodge transfer requests for physical shares purchased before April 1, 2019 that were previously rejected or not processed due to documentation deficiencies....
Marksans Pharma to Join Elara India Dialogue 2026 Investor Meet
Marksans Pharma Limited has scheduled participation in the Ashwamedh – Elara India Dialogue 2026, an investor and analyst meeting to be held on 2 September 2026 at the Hyatt in Santacruz East, Mumbai. The company emphasized that no unpublished price-...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 17, 2026
